Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa

Virology Journal

Anila Tariq Jahangiri²  Zahoor Ahmed Swati²  Najib ullah Khan²  Khaleeq Uz Zaman²  Sher Hayat Khan⁴  Sanaullah Khan¹  Aqib Iqbal²  Imtiaz Ali Khan³  Ijaz Ali²  Ihasn Ullah²  Latif ur Rehman² 

[1]Kohat University of Science and Technology, Kohat, Pakistan

[2]Institute of Biotechnology and Genetic Engineering, KPK Agricultural University, Peshawar, Pakistan

[3]Department of Entomology, KPK-Agricultural University, Peshawar, Pakistan

[4]Department of Animal Health, KPK-Agricultural University, Peshawar, Pakistan

关键词: KPK;    RT-PCR;    Genotype;    HCV;    IDUs;   

Others  :  1156489
DOI  :  10.1186/1743-422X-8-327

 received in 2011-03-26, accepted in 2011-06-28,  发布年份 2011

【 摘 要 】

Injection drug users (IDUs) are considered as a high risk group to develop hepatitis C due to needle sharing. In this study we have examined 200 injection drug users from various regions of the Khyber Pakhtunkhwa province for the prevalence of active HCV infection and HCV genotypes by Immunochromatographic assays, RT-PCR and Type-specific PCR. Our results indicated that 24% of the IDUs were actively infected with HCV while anti HCV was detected among 31.5% cases. Prevalent HCV genotypes were HCV 2a, 3a, 4 and 1a. Majority of the IDUs were married and had attained primary or middle school education. 95% of the IDUs had a previous history of needle sharing. Our study indicates that the rate of active HCV infection among the IDUs is higher with comparatively more prevalence of the rarely found HCV types in KPK. The predominant mode of HCV transmission turned out to be needle sharing among the IDUs.

【 授权许可】

   
2011 ur Rehman et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ryan KJ, Ray CG: Sherris Medical Microbiology. New York: McGraw Hill; 2004:551-2.
• [2]Rizzetto M: Viral hepatitis: introduction. In Oxford Textbook of Clinical Hepatology. Edited by McIntyre N, Benhamou JP, Bicher J, Rizzeto M, Rodes J. Oxford Medical Publication; 1992:529.
• [3]Lo Re V, Kostman JR: Management of chronic hepatitis C. Postgrad Med J 2005, 81:376-82.
• [4]WHO: Hepatitis C: Fact sheet No. 164. Geneva;
• [5]Takahashi M, Yamada G, Miyamato R, Doi TEndo, Tsuji T: Natural course of chronic hepatitis C. American J Gastroenterology 1993, 88:240-243.
• [6]Farhana M, Hussain I, Haroon TS: Hepatitis C: the dermatologic profile. J Pak Assoc Derm 2009, 18:171-181.
• [7]Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008, 8:69. BioMed Central Full Text
• [8]United Nations Programme on AIDS: AIDS Epidemic Update 2005. [http://controlpanel.irinnews.org/preview/Report.aspx?ReportID=23857] webciteGeneva;
• [9]Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF: Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 2000, 14(1):75-83.
• [10]Ball AL, Rana S, Dehne KL: HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep 1998, 113:170-181.
• [11]Parfitt T: Drug addiction and HIV infection on rise in Tajikistan. Lancet 2003, 362(9391):1206.
• [12]United Nations Office for the Coordination of Humanitarian Affairs: Uzbekistan: Drug-related HIV/AIDS cases on the rise in the south. [http://www.irinnews.org/print.asp?ReportID = 39932] webcite
• [13]United Nations Office on Drugs and Crime: 2005 World Drug Report, Volume I: Analysis. [http://www.unodc.org/pdf/WDR_2005/volume_1_web.pdf] webcite United Nations
• [14]United Nations Office on Drugs and Crime: 2005 World Drug Report, Volume II: Statistics. [http://www.unodc.org/pdf/WDR_2005/volume_2_web.pdf] webcite United Nations
• [15]Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, Strathdee SA: High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006., 3(26)
• [16]Kassi M, Kasi PM: Seroprevalences and coinfections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan. Trop Doct 2007, 37:43-45.
• [17]Ali A, Ahmad H, Ali I, Khan S, Zaidi G, Idrees M: Prevalence of active hepatitis c virus infection in district mansehra Pakistan. Virology Journal 2010, 7:334. BioMed Central Full Text
• [18]Idrees M: Development of an improved HCV genotyping assay for the detection of common genotypes and subtypes in Pakistan. J Virol Meth 2008, 150(1):50-56.
• [19]Mujeeb SA, Pearce MS: Temporal trends in hepatitis B and C infection in family blood donors from interior Sindh, Pakistan. BMC Infect Dis 2008, 8:43. BioMed Central Full Text
• [20]Hamid H, Iqbal R, Khan MH, Iftikhar B, Aziz S, Burki FK, sethi J, Hassan M, Nisar YB, Krishan J: Prevalence of hepatitis C in beta thalassaemic major. Gomal Journal of Medical Sciences 2008, 6(2):87-90.
• [21]Butt AK, Khan AA, Khan SY, Sharea I: Dentistry as a possible route of hepatitis C transmission in Pakistan. Int Dent J 2003, 53:141-144.
• [22]Srivastava AV, Czerska B, Williams C, Alesh I, Krese L, IIluang MA, Drost C, Smith C, Nemeh H, Tita C, Brewer R, Lanfear D: High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implanation. J Heart Lung Transplant 2009, 28(2):159-160.
• [23]Rahman M, Khan SA, Lodhi Y: Unconfirmed reactive screening tests and their impact on donor management. Pak J Med Sci 2008, 24(4):517-9.
• [24]Rehman I, Idrees M, Ali L, Butt S, Hussain A, Akbar H, Afzal S: Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan. Genetic Vaccines and Therapy 2011, 9:2. BioMed Central Full Text
• [25]Esfahani ZHS, Kardi MT, Edalati M: Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virology Journal 2010, 7:69. BioMed Central Full Text
• [26]Strathdee SA, Zafar T, Brahmbhatt H, Baksh A, Hassan SU: Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Dependence 2003, 71(1):17-24.